Evolus (EOLS) announced it has partnered with Symatese to commence distribution of Nuceiva, or botulinum toxin type A, in France. Nuceiva is approved by the European Commission for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows. Symatese, which has a direct presence in France, will be the exclusive distributor of Nuceiva in the country. This launch marks a milestone in Evolus’s commitment to strategic geographic expansion.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EOLS: